105 related articles for article (PubMed ID: 21939732)
21. Pro12Ala polymorphism in human peroxisome proliferator activated receptor gamma is associated with hyperlipidaemia in obstructive sleep apnoea hypopnoea syndrome.
Guan J; Yi H; Wu X; Su K; Tao M; Yin S
J Laryngol Otol; 2011 Oct; 125(10):1042-8. PubMed ID: 21669017
[TBL] [Abstract][Full Text] [Related]
22. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people.
Yang Z; Wen J; Tao X; Lu B; Du Y; Wang M; Wang X; Zhang W; Gong W; Ling C; Wu S; Hu R
Mol Biol Rep; 2011 Feb; 38(2):1145-50. PubMed ID: 20625834
[TBL] [Abstract][Full Text] [Related]
23. Interaction between PPARG Pro12Ala and ADIPOQ G276T concerning cholesterol levels in childhood obesity.
Johansson LE; Danielsson P; Norgren S; Marcus C; Ridderstråle M
Int J Pediatr Obes; 2009; 4(2):119-25. PubMed ID: 18645733
[TBL] [Abstract][Full Text] [Related]
24. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease.
Oliveira CP; Stefano JT; Cavaleiro AM; Zanella Fortes MA; Vieira SM; Rodrigues Lima VM; Santos TE; Santos VN; de Azevedo Salgado AL; Parise ER; Ferreira Alves VA; Carrilho FJ; Corrêa-Giannella ML
J Gastroenterol Hepatol; 2010 Feb; 25(2):357-61. PubMed ID: 19817962
[TBL] [Abstract][Full Text] [Related]
25. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
[TBL] [Abstract][Full Text] [Related]
26. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
[TBL] [Abstract][Full Text] [Related]
27. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
[TBL] [Abstract][Full Text] [Related]
28. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians.
Scacchi R; Pinto A; Gambina G; Rosano A; Corbo RM
Brain Res; 2007 Mar; 1139():1-5. PubMed ID: 17270153
[TBL] [Abstract][Full Text] [Related]
29. The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers.
Chao TH; Li YH; Chen JH; Wu HL; Shi GY; Liu PY; Tsai WC; Guo HR
Clin Sci (Lond); 2004 Nov; 107(5):461-6. PubMed ID: 15217350
[TBL] [Abstract][Full Text] [Related]
30. The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas.
Gong Z; Xie D; Deng Z; Bostick RM; Muga SJ; Hurley TG; Hebert JR
Carcinogenesis; 2005 Mar; 26(3):579-85. PubMed ID: 15564289
[TBL] [Abstract][Full Text] [Related]
31. The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.
Krawczyk M; Gruenhage F; Mahler M; Tirziu S; Acalovschi M; Lammert F
J Physiol Pharmacol; 2011 Jun; 62(3):369-75. PubMed ID: 21893698
[TBL] [Abstract][Full Text] [Related]
32. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD.
Gawrieh S; Marion MC; Komorowski R; Wallace J; Charlton M; Kissebah A; Langefeld CD; Olivier M
Dig Dis Sci; 2012 Apr; 57(4):952-7. PubMed ID: 22160635
[TBL] [Abstract][Full Text] [Related]
33. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.
Nakamuta M; Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Yada M; Yada R; Takemoto R; Fukuizumi K; Harada N; Taketomi A; Maehara Y; Nakashima M; Enjoji M
Int J Mol Med; 2008 Nov; 22(5):663-7. PubMed ID: 18949388
[TBL] [Abstract][Full Text] [Related]
34. Joint effect of peroxisome proliferator-activated receptor γ genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case-control study in Taiwan.
Wu MH; Chu CH; Chou YC; Chou WY; Yang T; Hsu GC; Yu CP; Yu JC; Sun CA
Breast Cancer Res Treat; 2011 Jun; 127(3):777-84. PubMed ID: 21140205
[TBL] [Abstract][Full Text] [Related]
35. The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease.
Cao CY; Li YY; Zhou YJ; Nie YQ; Wan YJ
Tohoku J Exp Med; 2012 Aug; 227(4):253-62. PubMed ID: 22820754
[TBL] [Abstract][Full Text] [Related]
36. Association of peroxisome proliferator activated receptor-γ gene with non-alcoholic fatty liver disease in Asian Indians residing in north India.
Bhatt SP; Nigam P; Misra A; Guleria R; Luthra K; Pandey RM; Pasha MA
Gene; 2013 Jan; 512(1):143-7. PubMed ID: 23031808
[TBL] [Abstract][Full Text] [Related]
37. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people.
Hui Y; Yu-Yuan L; Yu-Qiang N; Wei-Hong S; Yan-Lei D; Xiao-Bo L; Yong-Jian Z
Liver Int; 2008 Mar; 28(3):385-92. PubMed ID: 17999673
[TBL] [Abstract][Full Text] [Related]
38. PPARγ gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uygur Chinese population residing in Northwestern China.
Su Y; Liu Z; Yang L; Li Y; Jiang S; Yao H; Du G
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):894-904. PubMed ID: 32505733
[TBL] [Abstract][Full Text] [Related]
39. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease.
Vazquez-Chantada M; Gonzalez-Lahera A; Martinez-Arranz I; Garcia-Monzon C; Regueiro MM; Garcia-Rodriguez JL; Schlangen KA; Mendibil I; Rodriguez-Ezpeleta N; Lozano JJ; Banasik K; Justesen JM; Joergensen T; Witte DR; Lauritzen T; Hansen T; Pedersen O; Veyrie N; Clement K; Tordjman J; Tran A; Le Marchand-Brustel Y; Buque X; Aspichueta P; Echevarria-Uraga JJ; Martin-Duce A; Caballeria J; Gual P; Castro A; Mato JM; Martinez-Chantar ML; Aransay AM
Hepatology; 2013 Feb; 57(2):505-14. PubMed ID: 22961556
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients.
Gupta AC; Chaudhory AK; Sukriti ; Pande C; Sakhuja P; Singh Y; Basir SF; Sarin SK
Hepatol Int; 2010 Dec; 5(1):575-80. PubMed ID: 21442055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
